Quantcast
Last updated on April 19, 2014 at 18:42 EDT

OncoGenex to Webcast Discussion of Second Quarter 2012 Financial Results on Thursday, August 2, 2012

July 25, 2012

BOTHELL, WA, and VANCOUVER, July 25, 2012 /PRNewswire/ – OncoGenex
Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company’s
second quarter 2012 financial results will be released on Thursday,
August 2, 2012, and that the Company will host a conference call and
live webcast at 4:30 p.m. ET that afternoon. Management will discuss
the company’s financial results and provide an update on clinical
development programs for custirsen and OGX-427.

To access the webcast, log on to the Investor Relations page of the
OncoGenex website at www.OncoGenex.com. Alternatively, you may access the live conference call by dialing
(877) 606-1416 (U.S. & Canada) or (707) 287-9313 (International). A
webcast replay will be available approximately two hours after the call
and will be archived on www.OncoGenex.com for 90 days.

About OncoGenex Pharmaceuticals
OncoGenex is a biopharmaceutical company committed to the development
and commercialization of new therapies that address treatment
resistance in cancer patients. OncoGenex has a diverse oncology
pipeline, with each product candidate having a distinct mechanism of
action and representing a unique opportunity for cancer drug
development. OncoGenex and Teva Pharmaceutical Industries
Ltd. (NYSE: TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex’ lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer.
Phase 3 development of custirsen in treatment of advanced, unresectable
non-small cell lung cancer is expected to be initiated in 2012. OGX-427
is in Phase 2 clinical development, and OGX-225 is currently in
pre-clinical development. More information is available at www.OncoGenex.com.

Forward Looking Statements
This press release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements concerning our anticipated product development activities,
such as expected clinical trial initiation. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. These statements are based on management’s
current expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to differ
materially from those described in the forward-looking statements. Such
forward-looking statements are subject to risks and uncertainties,
including, among others, the risk that subsequent studies may not
confirm earlier trial results, the risk of delays in our expected
clinical trials, the risk that new developments in the rapidly evolving
cancer therapy landscape require changes in our clinical trial plans or
limit the potential benefits of our product and the other factors
described in our risk factors set forth in our filings with
the Securities and Exchange Commission from time to time, including the
Company’s Quarterly Reports on Form 10Q and Annual Report on Form 10-K
for fiscal year 2011. The Company undertakes no obligation to update
the forward-looking statements contained herein or to reflect events or
circumstances occurring after the date hereof, other than as may be
required by applicable law.

SOURCE OncoGenex Pharmaceuticals, Inc.


Source: PR Newswire